UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PTEN Signaling pathways in glioblastoma

Cancer biology & therapy, 2008-09, Vol.7 (9), p.1321-1325

Koul, Dimpy

2008

Volltextzugriff (PDF)

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Molecular cancer therapeutics, 2009-08, Vol.8 (8), p.2204-2210

2009

Volltextzugriff (PDF)

Antitumor Activity of NVP-BKM120―A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

Clinical cancer research, 2012-01, Vol.18 (1), p.184-195

2012

Volltextzugriff (PDF)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma

Neuro-oncology (Charlottesville, Va.), 2021-01, Vol.23 (6), p.920-931

2021

Volltextzugriff (PDF)

An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma

Cancer cell, 2011-09, Vol.20 (3), p.384-399

2011

Volltextzugriff (PDF)

Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma

Cancer research (Chicago, Ill.), 2005-03, Vol.65 (5), p.1678-1686

2005

Volltextzugriff (PDF)

APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death

Oncotarget, 2017-08, Vol.8 (33), p.54285-54296

2017

Volltextzugriff (PDF)

Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades

The Journal of biological chemistry, 2003-10, Vol.278 (41), p.40057-40066

2003

Volltextzugriff (PDF)

Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma

Molecular cancer therapeutics, 2005-11, Vol.4 (11), p.1681-1688

2005

Volltextzugriff (PDF)

Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma

Molecular cancer therapeutics, 2006-03, Vol.5 (3), p.637-644

2006

Volltextzugriff (PDF)

Exploratory analysis of the copy number alterations in glioblastoma multiforme

PloS one, 2008-12, Vol.3 (12), p.e4076-e4076

2008

Volltextzugriff (PDF)

PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway

Molecular and cellular biochemistry, 2007-06, Vol.300 (1-2), p.77-87

2007

Volltextzugriff (PDF)

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity

Oncogene, 2002-04, Vol.21 (15), p.2357-2364

2002

Volltextzugriff (PDF)

DDDR-13. MGMT FUNCTION DETERMINES THE DIFFERENTIAL RESPONSE OF ATR AND PARP INHIBITORS WITH DNA DAMAGING AGENTS FOR GBM THERAPY

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii101-vii101

2022

Volltextzugriff (PDF)

DRES-02. PARYLATION OF MGMT BY PARP IS REQUIRED FOR MGMT MEDIATED TEMOZOLOMIDE-INDUCED O6-METHYLGUANINE REPAIR: A NOVEL MECHANISM OF MGMT ACTION

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi71-vi72

2019

Volltextzugriff (PDF)

EXTH-06. ATR INHIBITORS AS MONOTHERAPY AND COMBINATORIAL THERAPY WITH TEMOZOLOMIDE IN PRECLINICAL GLIOBLASTOMA MODELS

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi164-vi164

2021

Volltextzugriff (PDF)

DDRE-33. PRECLINICAL THERAPEUTIC EFFICACY OF THE NOVEL BLOOD BRAIN BARRIER PENETRANT ATR INHIBITOR LR02 IN GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi81-vi81

2021

Volltextzugriff (PDF)

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma

Neuro-oncology (Charlottesville, Va.), 2022-10, Vol.24 (10), p.1712-1725

2022

Volltextzugriff (PDF)

DDRE-05. DECREASED EXPRESSION OF DNA DAMAGE RESPONSE PATHWAYS CORRELATES WITH SYNERGISTIC ACTIVITY OF TEMOZOLOMIDE WITH ATR INHIBITORS IN GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii62-ii62

2020

Volltextzugriff (PDF)

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Journal of clinical oncology, 2019-03, Vol.37 (9), p.741-750

2019

Volltextzugriff (PDF)

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity

Oncogene, 2002-04, Vol.21 (15), p.2357-2364

2002

Volltextzugriff (PDF)

CNSC-12. NEURONAL DIFFERENTIATION DRIVES THE ANTI-TUMOR EFFICACY OF MEK INHIBITION IN GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii24-vii24

2022

Volltextzugriff (PDF)

Abstract 2122: Downregulation of RGS10 induces PI3K/mTOR inhibitor resistance by Ras activation in glioblastoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2122-2122

2016

Volltextzugriff (PDF)

Abstract 2122: Downregulation of RGS10 induces PI3KmTOR inhibitor resistance by Ras activation in glioblastoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2122-2122

2016

Volltextzugriff (PDF)

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma

Clinical cancer research, 2020-03, Vol.26 (6), p.1395-1407

2020

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Aktive Filter

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(89)

Sprache

Englisch
(89)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(43)
Oncology
(34)
Humans
(32)
Animals
(19)
Mice
(16)
Cell Line, Tumor
(15)
Brain Neoplasms - Genetics
(10)
Clinical Neurology
(10)
Glioblastoma - Genetics
(10)
Glioblastoma - Pathology
(10)
Neurosciences & Neurology
(10)
Basic And Translational Investigations
(9)
Biological And Medical Sciences
(9)
Brain Neoplasms - Pathology
(9)
Mice, Nude
(9)
Brain Neoplasms - Drug Therapy
(8)
Glioblastoma
(8)
Male
(8)
Pten Phosphohydrolase
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PTEN Signaling pathways in glioblastoma

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Antitumor Activity of NVP-BKM120―A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma

An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma

Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma

APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death

Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades

Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma

Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma

Exploratory analysis of the copy number alterations in glioblastoma multiforme

PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity

DDDR-13. MGMT FUNCTION DETERMINES THE DIFFERENTIAL RESPONSE OF ATR AND PARP INHIBITORS WITH DNA DAMAGING AGENTS FOR GBM THERAPY

DRES-02. PARYLATION OF MGMT BY PARP IS REQUIRED FOR MGMT MEDIATED TEMOZOLOMIDE-INDUCED O6-METHYLGUANINE REPAIR: A NOVEL MECHANISM OF MGMT ACTION

EXTH-06. ATR INHIBITORS AS MONOTHERAPY AND COMBINATORIAL THERAPY WITH TEMOZOLOMIDE IN PRECLINICAL GLIOBLASTOMA MODELS

DDRE-33. PRECLINICAL THERAPEUTIC EFFICACY OF THE NOVEL BLOOD BRAIN BARRIER PENETRANT ATR INHIBITOR LR02 IN GLIOBLASTOMA

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma

DDRE-05. DECREASED EXPRESSION OF DNA DAMAGE RESPONSE PATHWAYS CORRELATES WITH SYNERGISTIC ACTIVITY OF TEMOZOLOMIDE WITH ATR INHIBITORS IN GLIOBLASTOMA

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity

CNSC-12. NEURONAL DIFFERENTIATION DRIVES THE ANTI-TUMOR EFFICACY OF MEK INHIBITION IN GLIOBLASTOMA

Abstract 2122: Downregulation of RGS10 induces PI3K/mTOR inhibitor resistance by Ras activation in glioblastoma

Abstract 2122: Downregulation of RGS10 induces PI3KmTOR inhibitor resistance by Ras activation in glioblastoma

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma

Aktive Filter

Suchergebnisse filtern